Clinical Trials Logo

Uterine Cancer clinical trials

View clinical trials related to Uterine Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04398446 Active, not recruiting - Breast Cancer Clinical Trials

Effect of Hemp-CBD on Patients With CIPN

Coala-T-CBD
Start date: May 27, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast, uterine, pancreatic, and colorectal cancer, and all stages of ovarian cancer in patients who received neoadjuvant or adjuvant therapy that included neurotoxic chemotherapeutic agents.

NCT ID: NCT04383210 Active, not recruiting - Breast Cancer Clinical Trials

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Start date: September 29, 2020
Phase: Phase 2
Study type: Interventional

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

NCT ID: NCT03934827 Active, not recruiting - Breast Cancer Clinical Trials

MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour

MICROBIOME
Start date: April 10, 2019
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery. 20 participants will receive open label MRx0518 in a preliminary safety phase. After successful evaluation by the Independent Safety Monitoring Committee (IDMC), a further 100 participants will be recruited to receive MRx0518/Placebo.

NCT ID: NCT03668340 Active, not recruiting - Uterine Cancer Clinical Trials

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Start date: October 22, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

NCT ID: NCT01650376 Active, not recruiting - Uterine Cancer Clinical Trials

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.

NCT ID: NCT01600040 Active, not recruiting - Cervical Cancer Clinical Trials

Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix

Start date: May 2013
Phase: N/A
Study type: Interventional

Proton beam radiation therapy is known to spare surrounding normal tissues from radiation. Proton beam radiation delivers less radiation beyond the area of the target tissues. This may reduce side effects that patients would normally experience with standard (photon) radiation therapy which tends to unavoidably include more normal tissue along with tumor target tissue. In this research study, the investigators are looking to determine if proton beam radiation is effective in controlling your cancer growth. The investigators are also looking to see if proton beam radiation can reduce side effects when compared to standard radiation treatment (photon radiation).